Endothelins and their receptors in cancer: identification of therapeutic targets.
Endothelins and their receptors are important in normal physiology, but have been implicated in various pathophysiological conditions. Members of the so-called "endothelin axis" are dysregulated in a wide range of human cancers, opening the door for novel anticancer therapies. Established cancer chemotherapeutic agents and drugs that target specific components of the endothelin axis have been combined with promising results, but more work is needed in this area. The endothelin axis affects numerous signaling pathways, including Ras, mitogen activated protein kinases, β-catenin/T-cell factor/lymphoid enhancer factor, nuclear factor-κB (NFκB), SNAIL, and mammalian target of rapamycin (mTOR). There is much still to learn about optimizing drug specificity in this area, while minimizing off-target effects. Selective agonists and antagonists of endothelins, their receptors, and upstream processing enzymes, as well as knockdown strategies in vitro, are providing valuable leads for testing in the clinical setting. The endothelin axis continues to be an attractive avenue of scientific endeavor, both in the cancer arena and in other important health-related disciplines.
Linus Pauling Institute, Oregon State University, Corvallis, OR 97331-6512, USA.
Rong
R
Wang
Roderick H
RH
Dashwood
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002470:Cell Survival / Q000502:physiology; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000502:physiology*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000503:physiopathology; D017466:Receptors, Endothelin / Q000819:agonists / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology
D000970:Antineoplastic Agents; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D017466:Receptors, Endothelin
J Med Chem. 2000 Feb 10;43(3):488-504
10669576
J Clin Oncol. 2003 Feb 15;21(4):679-89
12586806
Eur J Clin Invest. 2009 Jun;39 Suppl 2:74-7
19335749
Eur J Neurosci. 2004 Feb;19(4):1005-15
15009148
Eur Urol. 2009 May;55(5):1112-23
19042080
Expert Opin Pharmacother. 2010 Jun;11(8):1343-57
20426712
Cancer Invest. 2007 Dec;25(8):785-94
18058475
PLoS One. 2010 Jun 21;5(6):e11241
20574527
Br J Pharmacol. 2008 Mar;153(6):1105-19
17965745
Nat Rev Cancer. 2003 Feb;3(2):110-6
12563310
Am J Physiol Regul Integr Comp Physiol. 2010 Aug;299(2):R395-404
20538897
Hypertension. 2002 Dec;40(6):840-6
12468567
BJU Int. 2010 Oct;106(7):966-73
20840318
Can J Physiol Pharmacol. 2008 Aug;86(8):473-84
18758494
Arch Biochem Biophys. 2010 Sep 1;501(1):52-7
20361925
Am J Pathol. 2010 Aug;177(2):1004-16
20616339
Endocr Relat Cancer. 2007 Jun;14(2):233-44
17639040
Cancer Res. 2009 Mar 15;69(6):2669-76
19276384
Pharmacol Res. 2007 Mar;55(3):224-36
17317210
Curr Opin Nephrol Hypertens. 2010 Mar;19(2):134-9
20051851
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2806-11
19202075
Clin Sci (Lond). 2002 Aug;103 Suppl 48:302S-305S
12193109
Semin Cancer Biol. 2007 Oct;17(5):363-9
17555985
Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v23-4
18784133
Clin Cancer Res. 2008 Oct 1;14(19):6270-6
18829508
Mol Cancer Ther. 2006 Jun;5(6):1483-92
16818507
Cancer Lett. 2005 May 26;222(2):129-38
15863261
Breast Cancer Res Treat. 2010 Sep;123(2):345-57
19943105
J Cell Biochem. 2008 Jan 1;103(1):110-22
17486593
Can J Physiol Pharmacol. 2009 Dec;87(12):1009-18
20029537
Can J Physiol Pharmacol. 2010 Jun;88(6):676-81
20628434
Expert Opin Ther Targets. 2010 Jul;14(7):681-92
20446866
Expert Opin Ther Targets. 2010 Jun;14(6):647-54
20455789
Expert Opin Investig Drugs. 2010 May;19(5):641-52
20402599
Eur J Gastroenterol Hepatol. 2007 Sep;19(9):775-82
17700263
Expert Opin Investig Drugs. 2010 Jul;19(7):875-87
20528482
Pharmacol Res. 2010 Dec;62(6):457-64
20691268
Eur J Clin Invest. 2009 Jun;39 Suppl 2:78-87
19335750
Nature. 2001 Dec 20-27;414(6866):863-4
11780050
Curr Top Microbiol Immunol. 2011;344:129-48
20680802
Pharmacol Res. 2010 Apr;61(4):306-15
19931393
J Cell Physiol. 2007 Dec;213(3):589-602
17786953
J Biol Chem. 2009 Aug 14;284(33):22411-22425
19531493
Oncogene. 2005 Jan 20;24(4):597-604
15558022
J Biol Chem. 2003 Oct 17;278(42):41294-301
12907686
Cell Signal. 2010 Nov;22(11):1615-25
20466059
Cancer Lett. 2010 May 1;291(1):1-13
19717225
J Egypt Natl Canc Inst. 2008 Sep;20(3):216-23
20424651
Mol Cancer. 2010 Mar 30;9:69
20350333
Pharmacol Res. 2009 Nov;60(5):402-10
19666119
J Neurosci Res. 2005 Feb 1;79(3):303-9
15605384
Mol Cancer Ther. 2009 Aug;8(8):2452-60
19671740
FASEB J. 2002 Jan;16(1):87-9
11709493
Curr Med Chem. 2010;17(11):1059-66
20156159
Cancer. 2008 Nov 1;113(9):2478-87
18785254
Cancer Treat Res. 2004;118:197-212
15043194
Int J Biochem Cell Biol. 2008;40(8):1443-51
18325824
Br J Cancer. 2008 Oct 7;99(7):1114-20
18781169
ChemMedChem. 2006 Jan;1(1):96-105
16892341
Clin Cancer Res. 2009 Jul 15;15(14):4521-8
19567593
Jpn J Pharmacol. 2000 Sep;84(1):16-24
11043448
Cancer Res. 2008 Nov 15;68(22):9265-73
19010899
Oncol Res. 2009;17(8):383-6
19544975
Onkologie. 2010;33(6):300-4
20523093
Eur J Pharmacol. 2010 Dec 15;649(1-3):242-8
20854807
Biofactors. 2010 Sep-Oct;36(5):342-9
20730905
Pharmacol Res. 2001 Feb;43(2):111-26
11243712
Cell Tissue Res. 2010 Apr;340(1):103-15
20195637